Principal Investigator
Terrence Bradley
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240779
Clinical Trial Summary
A Phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced-phase MPNs
Phase
Phase I
Funding Agency/Sponsor
Institutional
Disease
Leukemia
Contact Information
Phone Number
305-243-2647